Age-relatedMacularDegeneration (ARMD) Drugs Market Size, Share, Growth, and Industry Analysis, By Type (Anti VEGF Drugs, Photosensitive Drugs, Others), By Application (Exudative ARMD, Atrophy ARMD), Regional Insights and Forecast to 2035

Age-relatedMacularDegeneration (ARMD) Drugs Market Overview

Age-relatedMacularDegeneration (ARMD) Drugs Market size, valued at USD 11130.45 million in 2026, is expected to climb to USD 15546.87 million by 2035 at a CAGR of 3.79%.

The Age-relatedMacularDegeneration (ARMD) Drugs Market is expanding due to the increasing aging population, rising retinal disease prevalence, and growing demand for anti-VEGF therapies. More than 196 million people globally were affected by age-related macular degeneration, while projections indicate the patient pool may exceed 280 million by 2040. Wet ARMD accounts for nearly 10% to 15% of total cases but contributes to almost 90% of severe vision loss incidents. Intravitreal injection procedures increased by over 35% during the last five years across major healthcare systems. The Age-relatedMacularDegeneration (ARMD) Drugs Market Report highlights strong adoption of biologics, retinal imaging technologies, combination therapies, and long-acting ophthalmic drug formulations across hospitals and specialty eye clinics.

The United States represents a major share of the Age-relatedMacularDegeneration (ARMD) Drugs Market, supported by a large elderly population and advanced ophthalmology infrastructure. More than 20 million adults in the U.S. are living with some form of macular degeneration, while nearly 11 million individuals are diagnosed with ARMD-related retinal disorders. Around 2 million Americans are affected by advanced ARMD stages associated with vision impairment. Over 8 million anti-VEGF injection procedures are performed annually in the country. Approximately 72% of ophthalmology centers in the U.S. have integrated AI-assisted retinal imaging systems for early disease detection. Increasing clinical trial activity and strong biologic drug penetration continue to support Age-relatedMacularDegeneration (ARMD) Drugs Industry Analysis across the United States.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Anti-VEGF therapy adoption increased by 64%, while retinal disease screening rates improved by 49% and biologic ophthalmic treatment preference surpassed 58% among elderly patients globally.
• Major Market Restraint: Nearly 41% of patients discontinue long-term injection therapy, while 37% report treatment burden concerns and 33% experience delayed diagnosis or treatment access limitations.
• Emerging Trends: Long-acting retinal implants witnessed 46% adoption growth, AI-assisted retinal diagnostics increased by 52%, and home-based monitoring technologies expanded by 39% across ophthalmology centers.
• Regional Leadership: North America accounts for nearly 43% of treatment procedures, while Europe contributes 29% and Asia-Pacific demonstrates 34% growth in retinal drug adoption rates.
• Competitive Landscape: The top five pharmaceutical manufacturers control approximately 67% of biologic ARMD drug distribution, while biosimilar competition expanded by 28% during recent market developments.
• Market Segmentation: Wet ARMD therapies contribute nearly 74% of treatment demand, hospital pharmacies account for 56% distribution share, and injectable biologics dominate with 69% usage rates.
• Recent Development: Clinical pipeline activity increased by 48%, gene therapy research expanded by 44%, and dual-action retinal biologics reported 36% improvement in treatment durability studies.

Age-relatedMacularDegeneration (ARMD) Drugs Market Latest Trends

The Age-relatedMacularDegeneration (ARMD) Drugs Market Trends indicate rising preference for long-duration anti-VEGF therapies and advanced retinal drug delivery technologies. More than 61% of ophthalmologists are shifting toward therapies requiring fewer annual injections. AI-enabled retinal imaging adoption increased by 52% across specialty eye hospitals and diagnostic centers. Biosimilar penetration in ophthalmology treatments grew by 31%, improving accessibility in emerging healthcare markets. Gene therapy clinical programs increased by 44%, while sustained-release implants demonstrated nearly 38% improvement in patient compliance rates. The Age-relatedMacularDegeneration (ARMD) Drugs Market Research Report also highlights increased investment in retinal biologics and precision ophthalmology.

Combination therapy approaches are gaining momentum in the Age-relatedMacularDegeneration (ARMD) Drugs Industry Report due to improved disease management outcomes. Approximately 47% of clinical-stage retinal therapies now involve multi-target mechanisms. Teleophthalmology consultations increased by 36%, supporting earlier ARMD diagnosis and follow-up monitoring. Home retinal monitoring devices experienced 42% growth in adoption among elderly populations. Dry ARMD pipeline expansion accelerated by 33% due to increasing geographic atrophy cases. 

Age-relatedMacularDegeneration (ARMD) Drugs Market Dynamics

The Age-relatedMacularDegeneration (ARMD) Drugs Market Dynamics are influenced by increasing retinal disease prevalence, expanding biologic drug innovation, and rising healthcare expenditure on vision care. More than 65% of ophthalmology investments are directed toward retinal disease management technologies and biologic therapies. The prevalence of advanced ARMD rises significantly among populations aged above 65 years, while nearly 30% of elderly adults exhibit early retinal degeneration symptoms. Hospital-based retinal treatment procedures increased by 41% over recent years. In addition, over 54% of ophthalmology research funding currently supports retinal drug discovery, sustained-release implants, and gene therapy development programs across major pharmaceutical markets.

DRIVER

"Growing elderly population and rising retinal disease burden"

The primary growth driver in the Age-relatedMacularDegeneration (ARMD) Drugs Market is the increasing geriatric population vulnerable to retinal degeneration disorders. Nearly 80% of advanced ARMD cases occur among individuals aged above 65 years. Globally, populations above 60 years are expanding rapidly, increasing the demand for retinal disease therapies and ophthalmology services. Wet ARMD contributes to almost 90% of severe vision loss cases despite representing a smaller share of total diagnoses. More than 62% of retinal specialists reported increasing patient volumes related to age-associated eye diseases. Anti-VEGF therapies demonstrated visual stabilization in approximately 94% of treated wet ARMD patients. 

RESTRAINTS

"High treatment burden and frequent injection requirements"

The Age-relatedMacularDegeneration (ARMD) Drugs Market faces significant restraints due to repeated intravitreal injection requirements and long-term treatment dependency. Nearly 41% of patients discontinue therapy within the first two years because of discomfort, travel challenges, and procedural anxiety. Frequent injection schedules impact elderly populations, especially in regions with limited retinal specialists. Approximately 37% of patients report difficulties attending monthly ophthalmology visits. High rates of underdiagnosis in developing economies also restrict treatment accessibility. More than 33% of individuals with early-stage ARMD remain untreated because of delayed diagnosis and limited awareness. The Age-relatedMacularDegeneration (ARMD) Drugs Market Research Report identifies reimbursement complexity and healthcare infrastructure gaps as additional barriers influencing market penetration. 

OPPORTUNITY

"Expansion of gene therapy and long-acting biologics"

Significant opportunities are emerging in the Age-relatedMacularDegeneration (ARMD) Drugs Market through gene therapy development and sustained-release retinal drug platforms. More than 44% of ophthalmology clinical trials are currently focused on advanced retinal biologics and genetic therapies targeting wet and dry ARMD conditions. Long-acting retinal implants reduced annual injection frequency by nearly 50% in several late-stage clinical studies. AI-driven retinal diagnostics improved early detection accuracy by approximately 52%, creating opportunities for preventive treatment models. Geographic atrophy treatment pipelines expanded by 39% due to increasing dry ARMD prevalence. Pharmaceutical companies are investing heavily in dual-action retinal drugs capable of targeting multiple disease pathways simultaneously. 

CHALLENGE

"Limited specialist availability and complex diagnosis procedures"

One of the major challenges affecting the Age-relatedMacularDegeneration (ARMD) Drugs Market is the shortage of retinal specialists and complex diagnosis requirements. More than 35% of rural healthcare regions globally lack advanced ophthalmology diagnostic infrastructure. Retinal imaging systems and optical coherence tomography devices remain concentrated in urban hospitals and specialty eye centers. Approximately 29% of ARMD patients receive diagnosis at advanced stages due to insufficient screening access. Patient compliance also remains difficult because nearly 40% of elderly individuals require caregiver support for treatment visits. The Age-relatedMacularDegeneration (ARMD) Drugs Industry Analysis highlights increasing healthcare pressure caused by rising patient volumes and limited specialist availability. 

Age-relatedMacularDegeneration (ARMD) Drugs Market Segmentation

The Age-relatedMacularDegeneration (ARMD) Drugs Market Segmentation is categorized by type and application, reflecting evolving treatment preferences across ophthalmology care settings. By type, anti-VEGF drugs dominate due to high adoption in wet ARMD treatment and improved visual stabilization rates. Photosensitive drugs are gaining demand in photodynamic therapy procedures, while other therapies include corticosteroids and emerging biologics. By application, exudative ARMD contributes the largest treatment volume because of severe vision loss risk, whereas atrophy ARMD therapies are expanding with increasing geographic atrophy diagnosis rates and ongoing retinal drug innovation programs globally.

Download Free Sample to learn more about this report.

BY TYPE

Anti VEGF Drugs: Anti VEGF drugs account for nearly 69% of the total Age-relatedMacularDegeneration (ARMD) Drugs Market share due to widespread use in wet ARMD management and strong clinical effectiveness in reducing retinal fluid accumulation. These therapies are preferred by more than 74% of retinal specialists because they improve visual acuity stabilization and slow retinal damage progression. Intravitreal anti VEGF injections represent over 80% of retinal injection procedures performed globally in ophthalmology centers. Patient response rates for anti VEGF therapies exceed 90% in moderate wet ARMD cases, making them the leading therapeutic category in the Age-relatedMacularDegeneration (ARMD) Drugs Market Analysis. Long-acting anti VEGF formulations are also gaining momentum, with treatment adherence improving by nearly 38% among elderly patients. Biosimilar anti VEGF products increased market penetration by approximately 31%, improving treatment accessibility in developing healthcare systems. 

Photosensitive Drugs: Photosensitive drugs contribute approximately 18% of the Age-relatedMacularDegeneration (ARMD) Drugs Market and are widely used in photodynamic therapy procedures targeting abnormal retinal blood vessel growth. These therapies are particularly effective for selected wet ARMD patients unsuitable for repeated anti VEGF injections. More than 42% of combination retinal treatment procedures integrate photosensitive drugs with laser-based therapy approaches. Clinical studies indicate that retinal leakage reduction rates exceed 63% in patients receiving targeted photodynamic interventions. Ophthalmology hospitals in advanced healthcare systems reported nearly 29% growth in demand for photosensitive retinal therapies due to lower procedural frequency requirements. The Age-relatedMacularDegeneration (ARMD) Drugs Industry Report also highlights growing adoption of precision laser-assisted treatment technologies that improve targeted retinal tissue protection. 

Others: The others segment includes corticosteroids, complement inhibitors, gene therapies, and emerging retinal biologics, collectively accounting for nearly 13% of the Age-relatedMacularDegeneration (ARMD) Drugs Market share. This segment is expanding rapidly due to increasing focus on dry ARMD and geographic atrophy treatment development. More than 44% of ongoing retinal clinical trials are concentrated within emerging therapy categories, particularly complement pathway inhibitors and gene-editing technologies. Retinal implant innovations improved drug release duration by approximately 40%, reducing treatment frequency and improving patient compliance. Around 27% of ophthalmology research investments are directed toward next-generation retinal biologics targeting inflammatory and degenerative pathways. 

BY APPLICATION

Exudative ARMD: Exudative ARMD represents nearly 74% of the total treatment demand within the Age-relatedMacularDegeneration (ARMD) Drugs Market due to its rapid vision loss progression and high dependence on anti VEGF therapies. This condition, commonly referred to as wet ARMD, contributes to almost 90% of severe blindness cases associated with retinal degeneration disorders. More than 8 million anti VEGF injection procedures are administered annually for exudative ARMD management worldwide. Clinical response rates exceed 92% among patients receiving early-stage biologic intervention. Approximately 67% of retinal imaging procedures are conducted for exudative ARMD diagnosis and monitoring because of its aggressive vascular complications. The Age-relatedMacularDegeneration (ARMD) Drugs Market Outlook highlights strong growth in sustained-release implants and dual-action biologics specifically developed for wet retinal diseases. Hospital ophthalmology departments account for over 58% of exudative ARMD treatment procedures globally. Increased awareness regarding early retinal screening and expanding teleophthalmology services continue to improve treatment accessibility and disease monitoring efficiency across aging populations.

Atrophy ARMD: Atrophy ARMD accounts for approximately 26% of the Age-relatedMacularDegeneration (ARMD) Drugs Market application share and is witnessing growing clinical focus due to increasing geographic atrophy prevalence among elderly populations. Nearly 5 million individuals globally are affected by advanced atrophic retinal degeneration associated with progressive vision impairment. Dry ARMD progression rates increase significantly in patients above 70 years, while approximately 48% of diagnosed cases eventually develop geographic atrophy complications. Research activity in atrophy ARMD therapies expanded by more than 39% as pharmaceutical companies accelerate complement inhibitor and regenerative retinal treatment development. The Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast indicates rising adoption of advanced retinal imaging technologies capable of improving early atrophy detection accuracy by nearly 51%. Around 34% of ophthalmology clinical trials currently target dry ARMD and retinal cell degeneration mechanisms. Increasing investments in neuroprotective retinal biologics, stem-cell therapies, and inflammation-targeting compounds are strengthening long-term opportunities in the atrophy ARMD treatment landscape.

Age-relatedMacularDegeneration (ARMD) Drugs Market Regional Outlook

The Age-relatedMacularDegeneration (ARMD) Drugs Market Regional Outlook demonstrates strong treatment adoption across developed and emerging healthcare systems. North America holds nearly 43% market share due to advanced retinal care infrastructure and high anti-VEGF procedure volumes. Europe contributes approximately 29% share supported by increasing elderly populations and expanding ophthalmology screening programs. Asia-Pacific accounts for nearly 22% share because of improving healthcare access, rising retinal disease awareness, and increasing biologic therapy penetration. Middle East & Africa represent around 6% share with gradual expansion in specialty eye hospitals and retinal diagnostic capabilities. The Age-relatedMacularDegeneration (ARMD) Drugs Market Analysis highlights increasing investment in retinal biologics and AI-assisted ophthalmology technologies globally.

Download Free Sample to learn more about this report.

NORTH AMERICA

North America dominates the Age-relatedMacularDegeneration (ARMD) Drugs Market with approximately 43% share driven by advanced ophthalmology infrastructure, strong biologic adoption, and increasing elderly population demographics. More than 20 million individuals in the region are affected by some form of macular degeneration, while nearly 8 million anti-VEGF injections are administered annually. Around 72% of retinal clinics utilize AI-supported imaging systems for diagnosis and treatment monitoring. The United States contributes the largest procedural volume, supported by widespread access to retinal specialists and specialty eye hospitals. More than 65% of ophthalmology clinical trials related to ARMD therapies are conducted across North America. Increasing adoption of sustained-release retinal implants and biosimilar biologics further strengthens Age-relatedMacularDegeneration (ARMD) Drugs Market Share throughout the regional healthcare system.

EUROPE

Europe accounts for nearly 29% of the Age-relatedMacularDegeneration (ARMD) Drugs Market share due to growing geriatric populations and expanding retinal disease management programs. More than 34 million individuals across Europe are estimated to experience early or intermediate retinal degeneration symptoms. Approximately 61% of ophthalmology hospitals in the region have integrated advanced optical coherence tomography systems for ARMD diagnosis. Wet ARMD therapies contribute nearly 70% of retinal drug demand across major European countries. Public healthcare reimbursement programs support broad biologic treatment accessibility, increasing patient compliance rates by nearly 37%. Around 48% of regional ophthalmologists are adopting long-duration anti-VEGF formulations to reduce injection frequency. The Age-relatedMacularDegeneration (ARMD) Drugs Industry Report also highlights rising investments in geographic atrophy research and precision retinal medicine throughout Europe.

ASIA-PACIFIC

Asia-Pacific represents approximately 22% of the Age-relatedMacularDegeneration (ARMD) Drugs Market share and demonstrates strong expansion potential because of rising healthcare modernization and increasing retinal disease awareness. More than 90 million elderly individuals across the region are considered vulnerable to age-related retinal disorders. Retinal imaging procedure volumes increased by nearly 46% within major urban healthcare systems. Japan, China, South Korea, and India remain key contributors to ophthalmology treatment growth. Around 39% of hospitals across developed Asia-Pacific countries are investing in AI-based retinal screening technologies. Biosimilar anti-VEGF penetration increased by approximately 34%, improving therapy affordability and treatment access. The Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast indicates increasing demand for dry ARMD therapies and teleophthalmology services as regional governments continue strengthening vision care infrastructure and elderly healthcare programs.

MIDDLE EAST & AFRICA

Middle East & Africa hold nearly 6% of the Age-relatedMacularDegeneration (ARMD) Drugs Market share, supported by gradual expansion of specialty ophthalmology services and increasing retinal disease awareness campaigns. More than 27% of urban healthcare facilities in the region now offer advanced retinal imaging diagnostics for ARMD identification. Gulf countries are leading regional adoption of biologic retinal therapies, while South Africa demonstrates increasing demand for anti-VEGF treatment procedures. Approximately 31% of ophthalmology centers in metropolitan regions have integrated digital retinal screening systems. Access limitations in rural areas continue affecting early diagnosis rates, with nearly 40% of patients identified during advanced disease stages. The Age-relatedMacularDegeneration (ARMD) Drugs Market Outlook highlights strong opportunities for telemedicine expansion, public health partnerships, and increased ophthalmology infrastructure investments throughout Middle Eastern and African healthcare systems.

List of Key Age-relatedMacularDegeneration (ARMD) Drugs Market Companies

• Roche
• Regeneron Pharmaceuticals
• Bayer
• Santen Oy
• Kanghong Pharmaceuticals
• Novartis
• Eli Lilly and Company
• TRACON Pharmaceuticals
• Pfizer
• GSK
• BIOCAD

Top Two Companies with Highest Share

• Roche: Holds nearly 28% market share supported by strong anti-VEGF biologic adoption and over 45% retinal specialist prescription preference globally.
• Regeneron Pharmaceuticals: Accounts for approximately 24% market share with more than 39% growth in long-acting retinal therapy utilization among ophthalmology clinics.

Investment Analysis and Opportunities

The Age-relatedMacularDegeneration (ARMD) Drugs Market is attracting significant investment activity due to rising retinal disease prevalence and expanding demand for biologic ophthalmic therapies. More than 54% of ophthalmology-focused pharmaceutical investments are directed toward retinal disease treatment research and advanced biologics development. Gene therapy programs for ARMD increased by approximately 44%, while sustained-release retinal implants received nearly 36% higher funding support from biotechnology investors. Around 47% of healthcare institutions globally are upgrading retinal imaging systems and digital ophthalmology platforms to improve early disease diagnosis and treatment monitoring. Investment in AI-supported retinal screening technologies increased by 52% across major healthcare economies.

Emerging opportunities within the Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast are linked to dry ARMD treatment innovation and geographic atrophy management. Approximately 39% of ongoing retinal clinical trials focus on complement inhibitors and regenerative retinal medicine. Biosimilar anti-VEGF manufacturing capacity expanded by nearly 33%, improving accessibility in developing healthcare markets. Teleophthalmology adoption increased by 41%, creating investment opportunities in remote retinal monitoring and home-based vision assessment systems. Around 29% of pharmaceutical partnerships now involve precision ophthalmology and dual-action biologic therapies designed to improve treatment durability and patient compliance rates. These developments continue strengthening Age-relatedMacularDegeneration (ARMD) Drugs Market Opportunities for pharmaceutical companies, healthcare investors, and retinal device manufacturers.

New Products Development

The Age-relatedMacularDegeneration (ARMD) Drugs Market is experiencing rapid new product development focused on long-duration therapies, gene-based retinal treatments, and advanced biologic formulations. More than 48% of retinal pipeline products currently target extended dosing intervals to reduce injection frequency among elderly patients. Dual-action anti-VEGF therapies demonstrated nearly 37% improvement in retinal fluid reduction during advanced-stage clinical evaluations. Pharmaceutical manufacturers are increasingly developing sustained-release implants capable of maintaining therapeutic effectiveness for longer treatment cycles. Around 34% of newly developed ophthalmic biologics include multi-target mechanisms designed to improve visual stabilization and reduce retinal inflammation simultaneously.

Innovation in dry ARMD therapies has accelerated significantly due to increasing geographic atrophy prevalence and unmet clinical demand. Approximately 42% of ophthalmology research programs now focus on complement pathway inhibitors and regenerative retinal technologies. AI-integrated retinal imaging systems improved disease progression monitoring accuracy by nearly 51%, supporting personalized ophthalmic treatment approaches. Home retinal monitoring devices experienced 38% product adoption growth among elderly patient populations. Additionally, over 31% of pharmaceutical companies are developing biosimilar retinal biologics to improve affordability and accessibility across emerging healthcare systems. These product advancements continue supporting Age-relatedMacularDegeneration (ARMD) Drugs Market Growth and competitive innovation within global ophthalmology sectors.

Five Recent Developments

• Roche expanded its retinal biologic portfolio with updated long-duration anti-VEGF treatment protocols, improving patient compliance rates by approximately 34% and reducing annual injection frequency across ophthalmology treatment centers during 2025.
• Regeneron Pharmaceuticals reported nearly 41% improvement in retinal fluid control during advanced clinical evaluations involving next-generation biologic therapies designed for wet ARMD management and long-term visual stabilization.
• Bayer increased investment in AI-supported retinal imaging integration, resulting in approximately 46% faster disease progression assessment and improved ophthalmology workflow efficiency within specialty eye hospitals during 2025.
• Novartis accelerated development of geographic atrophy therapies, with clinical programs demonstrating around 32% improvement in retinal lesion progression control among advanced dry ARMD patient populations.
• Pfizer strengthened ophthalmology research collaborations focused on gene-based retinal therapies, while early-stage treatment studies indicated nearly 29% enhancement in targeted retinal tissue preservation outcomes.

Report Coverage Of Age-relatedMacularDegeneration (ARMD) Drugs Market

The Age-relatedMacularDegeneration (ARMD) Drugs Market Report provides detailed analysis of retinal disease treatment trends, biologic therapy adoption, competitive landscape, and regional ophthalmology developments. The report evaluates major therapeutic categories including anti-VEGF drugs, photosensitive therapies, complement inhibitors, and emerging retinal biologics. More than 74% of current treatment demand originates from wet ARMD therapies, while geographic atrophy research programs increased by nearly 39%. The report also analyzes retinal imaging adoption, biosimilar penetration, and teleophthalmology expansion across healthcare systems.

The Age-relatedMacularDegeneration (ARMD) Drugs Industry Analysis further examines regional treatment distribution, hospital ophthalmology procedure trends, and investment activity in retinal medicine innovation. Approximately 52% of healthcare institutions globally are integrating AI-supported retinal diagnostics into ophthalmology workflows. The report includes insights regarding clinical pipeline expansion, patient compliance patterns, and specialist treatment preferences across North America, Europe, Asia-Pacific, and Middle East & Africa. In addition, the study evaluates strategic partnerships, retinal therapy advancements, and emerging opportunities in sustained-release implants and gene-based ophthalmic treatments.